RT Journal Article
SR Electronic
T1 Can we predict tuberculosis cure? What tools are available?
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1801089
DO 10.1183/13993003.01089-2018
VO 52
IS 5
A1 Delia Goletti
A1 Cecilia S. Lindestam Arlehamn
A1 Thomas J. Scriba
A1 Richard Anthony
A1 Daniela Maria Cirillo
A1 Tonino Alonzi
A1 Claudia M. Denkinger
A1 Frank Cobelens
YR 2018
UL http://erj.ersjournals.com/content/52/5/1801089.abstract
AB Antibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2–3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of “cure”. Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis http://ow.ly/tR3430m2NVQ